The largest community of pharma leaders

Arch Oncology Appoints Kirk Christoffersen as Chief Business Officer

BRISBANE, Calif. & ST. LOUIS–(BUSINESS WIRE)–Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced the appointment of Kirk Christoffersen as Chief Business Officer. In this newly-created position, Mr. Christoffersen will lead Arch Oncology’s corporate strategy and other business functions reporting to Julie Cherrington, Ph.D., President and Chief Executive Officer of Arch Oncology.

Recent Articles